[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

![Soeren_Berlin Avatar](https://lunarcrush.com/gi/w:24/cr:twitter::1129502882536017920.png) Sören Creutzburg [@Soeren_Berlin](/creator/twitter/Soeren_Berlin) on x XXX followers
Created: 2025-07-27 15:52:53 UTC

Appreciate it, Tyler! 

Regarding the FDA handling, I previously covered my stance in a reply:


As for capsid concerns (AAV similarity to Elevidys) the answer is more complex as there are countless contributing factors, but simply put: 

No, I’m not concerned at all. 
Opposite actually - I even see Sangamo and their capsids as mid-& long-term solution to the problems that $SRPT and many others are facing. 

Sngamo’s STAC-BBB capsid is significantly more advanced, showing ~700x-1400x higher brain delivery efficiency vs conventional AAV9 vectors (such as used by Elevidys). This increased efficiency greatly reduces dosing and safety concerns, positioning Sangamo more favorably with regulators despite smaller initial trial.

All data suggests they are best-in-class and global market leader when it comes to delivery efficiency and safety.


XXX engagements

![Engagements Line Chart](https://lunarcrush.com/gi/w:600/p:tweet::1949498233518018663/c:line.svg)

**Related Topics**
[longterm](/topic/longterm)
[$reymi](/topic/$reymi)

[Post Link](https://x.com/Soeren_Berlin/status/1949498233518018663)